IJCRR - 12(18), September, 2020
Pages: 42-47
Evaluation of Anxiogenic Effect of Pseudoephedrine in Albino mice
Author: Srinivasa Rao Konijeti, Kadiri Sunil Kumar, Sri Leela Movva, Muralikrishna K. S.
Category: Healthcare
[Download PDF]
Abstract:
Objectives: The study was designed with the rationale to investigate the anxiety-like behaviour with pseudoephedrine treatment in albino mice. Numerous reports of case studies suggest that pseudoephedrine treatment triggers anxiety symptoms in patients. Methods: Pseudoephedrine at doses 2 mg/kg and 5 mg/kg p.o was tested for its anxiogenic effect in albino mice by using elevated plus maze (EPM) and elevated zero mazes (EZM) models. Control and test group mice were treated with distilled water and pseudoephedrine for 15 days. The anxiogenic assessment was done on 15th day one hour after pretreatment with distilled water and pseudoephedrine. Results: In EPM study, there is a significant reduction in the number of entries (1.8 ± 0.63 with 5 mg/kg and 2.8 ± 1.39 with 2 mg/kg) and time spent in open arm (5.8 ± 0.47 seconds with 5mg/kg and 8.0 ± 1.98 seconds with 2mg/kg) with pseudoephedrine treatment at both doses when compared to control-treated mice (Number of entries=3.2 ±1.78 and time spent in open arm= 12 ± 0.14 seconds). In EZM there is a significant decrease in the number of entries in open arm (1.4 ± 0.21) and time spent in open arm (4.4 ± 1.72 seconds) with pseudoephedrine 5 mg/kg treatment when compared to control mice (Number of entries= 2.6 ± 1.35 and time spent in open arm= 11.6 ± 1.26 seconds). Conclusions: The reduction in the tendency of the mice to enter into the open arm after pseudoephedrine treatment indicates anxiety. This indicates that pseudoephedrine has an anxiety-inducing property.
Keywords: Pseudoephedrine, Anxiogenic, Elevated plus maze, Elevated zero maze, Open arm, Number of entries.
Citation:
Srinivasa Rao Konijeti, Kadiri Sunil Kumar, Sri Leela Movva, Muralikrishna K. S.. Evaluation of Anxiogenic Effect of Pseudoephedrine in Albino mice International Journal of Current Research and Review. 12(18), September, 42-47
References:
Frye CA, Walf AA, Rhodes ME, Harney JP. Progesterone enhances motor, anxiolytic, analgesic, and anti-depressive behaviour of wild-type mice, but not those deficient in type 1 5α-reductase. Brain research. 2004 Apr 9;1004(1-2):116-24.
2. Roy-Byrne PP, Craske MG, Stein MB, et al. A randomized effectiveness trial of cognitive-behavioural therapy and medication for primary care panic disorder. Arch Gen Psychiatry. 2005;62(3):290–298.
3. Stein MB, Sherbourne MG, Craske MG, et al. Quality of care for primary care patients with anxiety disorders. Am J Psychiatry. 2004;161(12):2230–2237.
4. Qiu A, Tuan TA, Ong ML, Li Y, Chen H, Rifkin-Graboi A, Broekman BF, Kwek K, Saw SM, Chong YS, Gluckman PD. COMT haplotypes modulate associations of antenatal maternal anxiety and neonatal cortical morphology. American Journal of Psychiatry. 2015 Feb 1;172(2):163-72.
5. Lockey RF. Rhinitis medicamentosa and the stuffy nose. Journal of allergy and clinical immunology. 2006 Nov 1;118(5):1017-8.
6. Mortuaire G, De Gabory L, François M, Massé G, Bloch F, Brion N, Jankowski R, Serrano E. Rebound congestion and rhinitis medicamentosa: nasal decongestants in clinical practice. A critical review of the literature by a medical panel. European annals of otorhinolaryngology, head and neck diseases. 2013 Jun 1;130(3):137-44.
7. Laccourreye O, Werner A, Giroud JP, Couloigner V, Bonfils P, Bondon-Guitton E. Benefits, limits and danger of ephedrine and pseudoephedrine as nasal decongestants. European Annals of Otorhinolaryngology, Head and Neck Diseases. 2015 Feb 1;132(1):31-4.
8. Mucha SM, Detineo M, Naclerio RM, Baroody FM. Comparison of montelukast and pseudoephedrine in the treatment of allergic rhinitis. Archives of Otolaryngology-Head and Neck Surgery. 2006 Feb 1;132(2):164-72.
9. Kanfer I, Dowse R, Vuma V. Pharmacokinetics of oral decongestants. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 1993 Nov 12;13(6P2):116S-28S.
10. P'ng XW, Akowuah GA, Chin JH. Acute oral toxicity study of Clinacanthus nutans in mice. International journal of pharmaceutical sciences and research. 2012 Nov 1;3(11):4202.
11. Kulkarni, Shrinivas K., Kulwinder Singh, and Mahendra Bishnoi. "Comparative behavioural profile of newer antianxiety drugs on different mazes." September 2008 Vol. 46 (4): 633-638.
12. Emamghoreishi M, Khasaki M, Aazam MF. Coriandrum sativum: evaluation of its anxiolytic effect in the elevated plus-maze. Journal of ethnopharmacology. 2005 Jan 15;96(3):365-70.
13. Matto V, Harro J, Allikmets L. The effects of cholecystokinin A and B receptor antagonists on exploratory behaviour in the elevated zero-maze in the rat. Neuropharmacology. 1997 Mar 1;36(3):389-96.
14. Dalton R. Mixed bipolar disorder precipitated by pseudoephedrine hydrochloride. South Med J 1990;83:64-5.
15. Erickson CH, McLeod RL, Mingo GG, Egan RW, Pedersen OF, Hey JA. Comparative oral and topical decongestant effects of phenylpropanolamine and d-pseudoephedrine. American journal of rhinology. 2001 Mar;15(2):83-90.
16. Bender B, Milgrom H. Neuropsychiatric effects of medications for allergic diseases. Journal of allergy and clinical immunology. 1995 Feb 1;95(2):523-8.
17. Bain D. Can the clinical course of acute otitis media be modified by systemic decongestant or antihistamine treatment? Br Med J 1983;287:654-6.
|